Experimental therapy of fetuses affected with congenital adrenal hyperplasia (CAH) has been reported by administering dexamethasone (Dex) to pregnant women at risk for carrying a CAH fetus. Such prenatal therapy can almost wholly eliminate virilization of the external genitalia of affected female fetuses, but only when treatment is started before 9 weeks of gestation. As it is not known whether the hypothalamic-pituitary-adrenal axis is functional at this time, and as the minimal effective doses of Dex are substantially supraphysiologic for the fetus, the mechanism of action of prenatal Dex treatment has been unclear.
Introduction
Mutations in the gene for steroid 21-hydroxylase cause over 90% of cases of congenital adrenal hyperplasia (CAH) (Miller 1994 , White & Speiser 2000 , which affects about 1 in 14 500 individuals (Therrell et al. 1998) . In affected children and adults, decreased 21-hydroxylase activity impairs the conversion of 17 -hydroxyprogesterone (17 OHP) to 11-deoxycortisol, causing glucocorticoid deficiency which, in turn, results in increased secretion of adrenocorticotropin (ACTH). Increased ACTH stimulates the steroidogenic steps prior to 21-hydroxylase resulting in overproduction of adrenal C-19 steroid precursors of androgens. The genitalia of affected 46XX genetic females can be severely virilized, suggesting that the same physiology occurs in utero. To suppress fetal ACTH and consequently ameliorate genital virilization of affected females, David and Forest (1984) and Evans et al. (1985) first proposed the administration of glucocorticoids such as dexamethasone (Dex) early in pregnancy to women at risk for delivering an infant with CAH (based on having delivered a previous child with CAH). This approach has been refined and popularized by New and colleagues (Speiser et al. 1990 , Mercado et al. 1995 , New et al. 2001 and by Forest and colleagues (Forest et al. 1989 (Forest et al. , 1993 (Forest et al. , 1998 . Experience with over 200 fetuses treated to term indicates that prenatal administration of Dex substantially ameliorates or eliminates the genital virilization of affected females, if the treatment is started less than 9 weeks following fertilization (Forest et al. 1998 , New et al. 2001 . However, this approach remains controversial (Seckl & Miller 1997 , Miller 1998 , and the worldwide pediatric endocrine community has agreed that it is not 'standard-of-care' and requires prospective protocols approved by local human experimentation committees (Joint LWPES/ESPE CAH Working Group 2002).
The mechanism of action of Dex in this experimental prenatal treatment of CAH has been unclear. Dex, rather than cortisone or prednisone, is used because it is not an effective substrate for placental 11 -hydroxysteroid dehydrogenase 2 (11 HSD 2) (White et al. 1997 ) and hence is not inactivated by the placenta. The best clinical results are obtained when Dex treatment is started very early in gestation, at 6-8 weeks post conception, before the time when testicular androgens begin to virilize the external genitalia in normal male development at 6-14 weeks (Wilson et al. 1993) . Although immunoreactive ACTH can first be detected in the fetal pituitary at about 8 weeks of gestation (Asa et al. 1986 (Asa et al. , 1988 , adrenal development appears to be normal in first-trimester anencephalic fetuses, suggesting that early adrenal development may be independent of ACTH (Gray & Abramovich 1980) . Furthermore, fetal concentrations of cortisol are normally about one-tenth of those of the mother (Partsch et al. 1991 , Kari et al. 1996 and the typical doses of Dex (20 µg/kg maternal weight) are about 3 to 6 times supraphysiological for the mother. Thus, if Dex freely crosses the placenta, the effective glucocorticoid dose delivered to the fetus may be up to 60 times supraphysiologic.
While the glucocorticoid feedback sensitivity of the fetal hypothalamic-pituitary axis is unknown, it has appeared that the high dosage requirements are consistent with a mechanism other than suppression of the hypothalamicpituitary-adrenal (HPA) axis. One possibility is that Dex might affect the adrenal directly. If the adrenal is normally responsive to hypothetical ultra-short loop feedback by glucocorticoids, one might expect that high glucocorticoid concentrations in the range of those found within the adrenal, rather than those found within the circulation, would exert such an effect. A preliminary study in our laboratory in 1990 suggested that Dex may directly suppress the transcription of the gene for P450c17 (17 -hydroxylase/17,20 lyase) (Brentano et al. 1990 ). Therefore we explored the possibility that high concentrations of Dex may exert a direct intra-adrenal ultra-short loop feedback on steroidogenesis.
Materials and Methods

Steroid production
The adherent NCI-H295A subline (Rodriguez et al. 1997) of human NCI-H295 cells (Gazdar et al. 1990 , Staels et al. 1993 ) was grown to confluence in 6-well plates in RPMI medium supplemented with 2% FBS, penicillin (100 U/ml), 5 µg/ml insulin, 5 µg/ml transferrrin and 5 ng/ml selenite, as described (Staels et al. 1993 , Rodriguez et al. 1997 . Concentrations of 0·1, 1·0, 10 and 100 µM Dex (Sigma) in 50 µl ethanol were added for 6 h, then 20 000 c.p.m. [
14 C]pregnenolone or [ 14 C]progesterone (NEN Life Science, Boston, MA, USA) were added for 1 h. The medium (2 ml) was harvested and steroids were extracted with 8 ml methylene chloride:iso-octane (1:1), dried under N 2 , dissolved in 20 µl methylene chloride, and analyzed by thin layer chromatography on Whatman PE Sil G/UV silica gel plates (Maidstone, Kent, UK) as described (Auchus et al. 1998) . Chromatograms were developed with 3:1 chloroform:ethyl acetate to resolve 17-hydroxysteroids (Lin et al. 1991) or 300:20:1 methylene chloride:methanol:H 2 O to resolve 17-deoxysteroids (Fardella et al. 1995) as described. The 14 C steroids were detected by phosphorimaging and identified by co-chromatography with a panel of labeled and unlabeled steroid standards.
RNA analysis
Total RNA was extracted from NCI-H295A using 0·5 ml TriReagent (Molecular Research Center, Cincinnati, OH, USA) (Chomczynski 1993) according to the manufacturer's instructions. Dot-blot analysis was performed as described (Voutilainen et al. 1986) . RNA samples were denatured in 7·5% formaldehyde and 6 SSC (0·9 M NaCl, 0·09 M sodium citrate) at 80 C for 20 min and then blotted to nitrocellulose filters (Amersham). Filters were prehybridized in buffer containing 50% formamide, 6 SSC, 0·1% ficoll, 0·1% BSA, 0·1% polyvinylpyrrolidone, 100 µg/ml salmon sperm DNA and 100 µg/ml yeast tRNA for 16 h at 42 C before probe was added. Hybridization was performed for 4 h using labeled human cDNA for P450c17 (Chung et al. 1987) , P450scc (cholesterol side chain cleavage enzyme) (Chung et al. 1986) , or 3 HSDII (3 -hydroxysteroid dehydrogenase II) (Rheaume et al. 1991) . Probes were labeled with [ -32 P]dCTP as described (Feinberg & Vogelstein 1984) . The uniformity of the loading was tested using a labeled human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe generated by PCR. The filters were washed in 0·2% SSC, 0·1% SDS, 4 times at 50 C and analyzed by phosphorimaging.
Transfection and dual luciferase reporter assay
Luciferase reporter constructs containing 2500 bp of the 5 flanking DNA of the P450c17 gene (Rodriguez et al. 1997) or 2327 bp of the 5 flanking region of the P450scc gene (Moore et al. 1990) , were transfected into NCI-H295A cells using the calcium phosphate-DNA coprecipitation method (Gorman et al. 1982) as described (Rodriguez et al. 1997) . For transfection, the RPMI medium was replaced by DMEM-H16 supplemented with 10% FBS and penicillin (10 U/ml) as described (Rodriguez et al. 1997) . After 12 h, the medium was replaced with fresh medium containing various concentrations of Dex and incubated for 24 h. Cellular extracts were assessed for luciferase activity by the dual luciferase reporter assay system (Promega). Transfection efficiencies were normalized by co-transfecting the cells with the pRL-CMV plasmid (Promega) expressing the Renilla luciferase gene driven by the CMV promoter.
Results
To determine whether dexamethasone exerts an intraadrenal ultra-short loop feedback inhibition on steroidogenesis, we used human adrenal NCI-H295A cells as a model of the human fetal adrenal (Staels et al. 1993) . These cells secrete the same steroids that are produced by the human adrenal (Gazdar et al. 1990) , and express all the enzymes normally found in the human fetal adrenal gland (Staels et al. 1993) . The regulation of steroid hormone synthesis, the regulation of the mRNAs for the steroidogenic enzymes and the transcriptional regulation of their cognate genes all respond in the physiologically expected fashions, providing excellent evidence that the regulation of steroidogenesis in these cells is a useful model for the regulation of steroidogenesis in the human fetal adrenal (Gazdar et al. 1990 , Rainey et al. 1993 , Staels et al. 1993 , Rainey et al. 1994 , Bird et al. 1995 , Rodriguez et al. 1997 , Bird et al. 1998 , Wijesuriya et al. 1999 , Lin et al. 2001 . The potential action of Dex on the adrenal could conceivably be exerted at any of three levels. First, Dex might exert an action directly on steroidogenic enzymes, either as an inhibitor of enzymatic activity or by altering the stability of the enzymes themselves; secondly, Dex might alter the stability of the mRNAs encoding steroidogenic enzymes; thirdly, it might have a direct effect to suppress transcription of genes encoding steroidogenic enzymes.
Examining the conversion of [ 14 C]pregnenolone to downstream steroids in a short (6 h) incubation period provides a measure of the potential action of Dex on steroidogenic enzymes. Under basal conditions, NCI-H295A cells convert pregnenolone to the 4 steroids, progesterone, 17 OHP, deoxycorticosterone (DOC), 11-deoxycortisol, and androstenedione, and secrete very little of the 5 steroids, 17 -hydroxypregnenolone (17 OHPreg) and dehydroepiandrosterone (DHEA) (Gazdar et al. 1990 ). Concentrations of Dex up to 1 µM had no effect on steroidogenesis, but 10 µM Dex decreased secretion of 11-deoxycortisol and 17 OHP and increased secretion of DOC, suggesting an inhibitory effect on 17 -hydroxylase activity (Fig. 1) . When the cells were incubated with [
14 C]progesterone, thus providing a 4 steroid precursor, 10 µM Dex again inhibited 17 -hydroxylase activity, increasing secretion of DOC and decreasing secretion of 17 OHP and 11-deoxycortisol (Fig.  2) . Thus Dex inhibited 17 -hydroxylase activity, but only at the very high concentrations that are known to act as a competitive inhibitor of P450c17 (Lee et al. 1999) .
To determine whether Dex exerts an effect on the abundance of steroidogenic enzyme mRNAs, we measured the abundance of the mRNAs for P450scc (the quantitative regulator of steroidogenesis), P450c17 (the qualitative regulator of steroidogenesis) and 3 HSDII. Incubating NCI-H295A cells with 0·1 to 100 µM Dex for 72 h did not change the abundance of any of these mRNAs (Fig. 3) . As a potential effect of Dex might be to inhibit tropic stimulation, we again incubated NCI-H295A cells with 0·1 to 100 µM Dex for 72 h, but added 1 mM 8Br-cAMP during the last 24 h. The cAMP treatment increased P450scc mRNA eight-to ninefold and increased P450c17 and 3 HSD mRNAs about twofold, but this action of cAMP was not influenced by Dex (Fig. 4) . The substantially greater response of P450scc mRNA to cAMP compared with P450c17 mRNA is consistent with prior observations in NCI-H295 cells (Staels et al. 1993) and in primary cultures of human fetal adrenal cells (Di Blasio et al. 1987) .
Finally, to determine whether Dex exerts a direct effect on transcription of genes encoding steroidogenic enzymes, Figure 1 Metabolic conversion of pregnenolone in NCI-H295A cells incubated with Dex. Cells were incubated with [ 14 C]pregnenolone and with the indicated concentrations of Dex for 6 h, and the generated metabolites were analyzed in two different chromatographic systems: chloroform-ethyl acetate 3:1 (A) and methylene chloride-methanol-H 2 O, 300:20:1 (B). The identity of the identified radioactive steroids was confirmed by co-chromatography with standards for pregnenolone (Preg), progesterone (Prog), 17 OHP, 17 OHPreg, androstenedione (Andro), DOC, 11-deoxycortisol (11 Deoxycort), corticosterone, aldosterone, and hydrocortisone.
we transfected NCI-H295A cells with promoter/reporter constructs containing 2·3 kb DNA from the human P450scc promoter or 2·5 kb DNA from the human P450c17 promoter. These DNA segments contain all of the elements known to participate in the regulation of these key genes (Brentano et al. 1990 , Moore et al. 1990 , Rodriguez et al. 1997 , Lin et al. 2001 . No concentration of Dex up to 100 µM had a detectable effect on the transcription of these constructs during a standard (Lin et al. 2001 ) 24-h incubation (Fig. 5) . Thus, although high concentrations of Dex inhibited 17 -hydroxylase activity, they had no detectable affect on the transcription of genes encoding steroidogenic enzymes, or the half-life of their encoded mRNAs.
Discussion
In order for prenatally administered Dex to suppress the genital virilization of CAH female fetuses, it must be administered at very high doses very early in gestation, suggesting Dex may act by a mechanism other than suppressing the HPA axis.
An early report indicated that intracellular steroids exert regulatory effects on the activity of the steroidogenic enzymes in adrenals, testis and ovaries, thus regulating the pattern and the rate of steroid production (Gower & Cooke 1983) . In bovine and guinea pig adrenals, androstenedione can inhibit 21-hydroxylase activity, increasing C-19 steroid synthesis and inhibiting glucocorticoid production (Hornsby 1982 , Belanger et al. 1995 . However, the potential effects of steroids on their own synthesis in adrenocortical cells is not clear. ACTH induces accumulation of mRNAs for P450scc and P450c17 in primary cultures of human fetal adrenal cells (Di Blasio et al. 1987) , and Dex inhibited the ACTH-induced accumulation of P450scc and P450c17 mRNAs in cultured bovine adrenocortical cells (Trzeciak et al. 1993) , but Dex enhanced ACTH induction of corticosteroid production in ovine adrenocortical cells (Darbeida & Durand 1988) , and phorbol ester induction of 3 -hydroxysteroid dehydrogenase in NCI-H295R cells (Feltus et al. 2002) . Thus, we investigated the potential role of Dex as a potential regulator of fetal adrenal steroidogenesis.
Human adrenal NCI-H295A cells are the best available model of the human fetal adrenal. They produce all of the steroids and express all of the enzymes of human adrenal steroidogenesis, and regulate the genes encoding these enzymes in a manner similar to that of human fetal adrenal cells (Gazdar et al. 1990 , Staels et al. 1993 , Rainey et al. 1993 , 1994 , Bird et al. 1995 , Rodriguez et al. 1997 , Bird et al. 1998 , Wijesuriya et al. 1999 , Lin et al. 2001 . They also express insulin-like growth factor-II (Staels et al. 1993) , a marker of the fetal but not the adult adrenal (Voutilainen & Miller 1988) , and express functional glucocorticoid receptor (Fassnacht et al. 2000 , Feltus et al. 2002 . Nevertheless, since this is a transformed cell line, there may be unknown aspects of the regulation of steroidogenesis that differ between NCI-H295A cells and the human fetal adrenal gland in vivo.
In human adrenal replacement therapy, less than 0·2 mg Dex per m 2 of body surface area appears to be physiologic (Rivkees & Crawford 2000) , and estimations of the biopotency of Dex based on its ability to suppress adrenal C-19 steroid secretion (Rivkees & Crawford 2000) and growth (Styne et al. 1977) suggest that Dex is 80 times more potent than hydrocortisone, rather than the generally-cited factor of 30 based on anti-inflammatory effects. The normal secretory rate of cortisol is 6-7 mg/ m 2 /day (Linder et al. 1990 , Esteban et al. 1991 , Kerrigan et al. 1993 , which would thus translate to a Dex equivalent of about 0·1 mg/m 2 . The higher therapeutic potency of Dex is related to its longer half-life than cortisol, its poor binding to corticosteroid binding globulin and to its sevenfold higher binding affinity to the glucocorticoid receptor (Manz et al. 1983 , Derendorf et al. 1993 . However, the typical dose of Dex used in the prenatal treatment of CAH is 20 µg/kg/day (Forest et al. 1989 , Speiser et al. 1990 , Forest et al. 1993 , Mercado et al. 1995 , Forest et al. 1998 , New et al. 2001 . Thus, in a 60 kg woman having a body surface area of 1·2 m 2 , the physiologic replacement dose of Dex is probably less than 0·2 mg, but the dose used in the prenatal treatment of CAH is 1·2 mg. This is about 6 times supraphysiological for the mother, and, as fetal cortisol concentrations are normally one-tenth those in the mother (Partsch et al. 1991 , Kari et al. 1996 , about 60 times supraphysiological for the fetus. This suggested that the action of Dex in experimental prenatal therapy might not be on the HPA axis.
The typical intra-adrenal concentrations of cortisol late in gestation and in newborns are about 3·7 to 7·4 µM and up to 47·6 µM in adults (Dickerman et al. 1984) , whereas the circulating concentrations are less than 0·1 µM in the fetus (Partsch et al. 1991 , Kari et al. 1996 and 0·1 to 0·7 µM in adults. Thus a hypothetical intra-adrenal of three independent experiments, each performed in triplicate. There was no effect (P.0·05) on the promoter activity of P450scc or P450c17 at any concentration of Dex tested. ultra-short loop feedback mechanism might be expected to act at concentrations 50 to 100 times higher than those found in the circulation, i.e. at > 50 µM cortisol, which would be equivalent to 0·5 to 1 µM Dex. However, the only action of Dex we observed in concentrations up to 100 µM was a decrease in 17 -hydroxylase activity at 10-100 µM Dex, which is consistent with the known action of Dex as a competitive inhibitor of P450c17 with a K i of 87 µM (Lee et al. 1999) . Such high concentrations of Dex are far beyond the concentrations that might approximate the intra-adrenal concentration of cortisol and far beyond those achieved by current prenatal protocols.
Thus our data suggest that the Dex used in experimental prenatal treatment of CAH does not work by an intra-adrenal mechanism. The mechanism by which Dex suppresses androgen production during prenatal treatment of CAH remains unclear.
